Scientists identify possible gene target for treating a form of lymphoma

Dec 22, 2010

Researchers have identified a mutation in a gene that could lead to targeted therapies for certain lymphoma patients whose cure rates are currently poor. Mutation of the MYD88 gene was found to be one of the most frequent genetic abnormalities in a form of cancer known as diffuse large B cell lymphoma. MYD88 encodes a protein that is crucial for the normal immune response to invading microorganisms. New experiments show a mutation in the MYD88 protein sequence can cause uncontrolled cellular signaling, leading to survival of malignant cells. The study, led by researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, appeared online in Nature, Dec. 22, 2010.

Single mutations, or more often, combinations of gene mutations, can lead to the development of cancers such as . Lymphoma is a cancer of the blood that arises from infection-fighting . , a type of non-Hodgkin’s lymphoma, is the most common form of this disease. There are three subtypes of diffuse large B cell lymphoma, of which the activated B cell-like (ABC) form has the poorest three-year survival outcome of 40 percent.

Louis M. Staudt, M.D., Ph.D., Metabolism Branch, Center for Cancer Research, NCI, and colleagues, have worked to identify proteins that play a role in the development of the ABC subtype because these proteins may provide targets to improve the treatment of patients with this form of lymphoma. To identify these critical proteins, the researchers performed a genetic screen in which thousands of genes were inactivated. They found that ABC were killed when they inactivated the genes encoding MYD88 and IRAK1, another cell signaling protein that works with MYD88.

The scientists then looked for genetic mutations that might explain why the ABC lymphoma cells were so dependent upon MYD88. Sequencing of the MYD88 gene in 382 lymphoma biopsy samples revealed that 29 percent of ABC lymphoma samples had the same mutation, which altered a single amino acid in the MYD88 protein, but this mutation was rare or absent in other lymphoma subtypes. The mutant form of MYD88 sustained the survival of the ABC lymphoma cells but the non-mutated version did not, suggesting that mutations in the MYD88 gene could play an important role in the development of ABC diffuse large B cell lymphomas.

To understand how MYD88 might promote ABC lymphoma cell survival, the researchers examined proteins that interact with MYD88 in the lymphoma cells. The mutant form of MYD88 spontaneously assembled a protein complex that included IRAK1, identified in the genetic screen, and a related protein, IRAK4. In this protein complex, IRAK4 functioned as an enzyme to modify IRAK1, which was required for the mutant MYD88 to promote lymphoma cell survival. This particular finding may have direct therapeutic implications since pharmaceutical companies are developing IRAK4 inhibitors for use in inflammatory and autoimmune diseases, according to the scientists.

“We believe the results of this study may provide a method to identify patients with the ABC subtype of diffuse large B cell lymphoma whose tumors may depend upon MYD88 signaling and who may therefore benefit from therapies targeting IRAK4 alone or in combination with agents targeting other regulatory pathways that sustain the survival of these lymphoma cells,” said Staudt.

Explore further: Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

Related Stories

New mutation linked to non-Hodgkin's lymphoma

Nov 01, 2010

Some patients with non-Hodgkin lymphoma (NHL) -- a cancer of B cells -- harbor a particular mutation in the gene encoding the receptor for B cell activating factor (BAFF), according to a paper published online on November ...

SHIP protein identified as a B-cell tumor suppressor

Oct 19, 2010

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably ...

News from Cancer: Risk factors for deadly form of lymphoma

Jul 07, 2008

A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin's lymphoma, is on the rise, most frequently striking men, Caucasians and older individuals. The study, published in the August ...

Recommended for you

Spicy treatment the answer to aggressive cancer?

Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.